St Jude begins US trial for HF (heart failure) stimulation device:
This article was originally published in Clinica
Executive Summary
St Jude Medical has begun the US portion of its clinical trial to assess its Genesis biventricular resynchronisation device as a treatment for heart failure (HF). The VecToR (Ventricular Resynchronization Therapy Randomized) trial will evaluate low-voltage biventricular stimulation versus no stimulation therapy and will collect and assess data on more than 420 HF patients from around 40 centres worldwide, said the St Paul, Minnesota company. The Genesis system consists of three components - the Frontier 3x2 stimulation device, the Aescula LV left-heart lead and a catheter delivery system.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.